Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Qingdao Borson Tai Technology Co. Ltd. holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity is confined to 1 distinct art unit, reflecting the company's technical focus. The emphasis on Biotechnology & Pharmaceuticals suggests that the company's current research is centered on biological or pharmaceutical developments.
The company's prosecution involves a distinct examiner. IVANOVA, SVETLANA M is the busiest examiner for the portfolio. This examiner is currently managing the pending office action. The presence of a single examiner and 1 distinct art unit for the pending workload indicates a focused examination process for the company's current applications. This centralized arrangement can facilitate a more direct dialogue with IVANOVA, SVETLANA M, potentially streamlining the path toward resolution for the 1 pending office action. The involvement of a single distinct examiner ensures that the prosecution strategy remains consistent across the active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568114 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | IVANOVA, SVETLANA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568114 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | IVANOVA, SVETLANA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568114 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | IVANOVA, SVETLANA M | 1627 | §102§112 | Non-Final OA | — | Pending | Dec 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQingdao Borson Tai Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Svetlana M Ivanova has the most, with 1 of Qingdao Borson Tai Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
